Life science company ValiRx Plc (AIM: VAL), announced on Monday that it has concluded its Evaluation project with Imperial College London, previously announced on 21 March 2024.
Following the collaboration agreement, the company synthesised, tested and profiled drug candidates from the Dual Kinase series, comparing them with established therapeutics in various tests.
While initial results were promising, ValiRx has decided to return the project to Imperial College London for further development, with no additional financial commitment from ValiRx. As part of this, the current collaboration agreement has been terminated and responsibility for maintaining the intellectual property will revert to the university.
ValiRx is focused on early-stage cancer therapeutics and women's health, while accelerating the translation of innovative science into clinical development, leveraging its expertise to guide drug candidates from pre-clinical studies to market readiness.
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
Faron Pharmaceuticals' bexmarilimab receives FDA Orphan Drug Designation for MDS
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
Innovent Biologics doses first patient in registrational study assessing IBI363
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
AstraZeneca's camizestrant shows significant PFS benefit in HR+ breast cancer
FDA accepts Telix Pharmaceuticals' BLA for Zircaix and grants Priority Review
Summit Therapeutics and Pfizer partner to evaluate ivonescimab with ADCs in solid tumor trials
Bristol Myers Squibb's application for Opdivo-Yervoy combo in colorectal cancer accepted by U.S. FDA
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Sectra and Siemens Healthineers collaborate to enhance radiology diagnostics
ValiRx Plc concludes evaluation project with Imperial College London